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background:  Digoxin is a commonly used therapy for rate control in atrial fibrillation (AF). However, there have been discrepant findings 
on the association between digoxin use and risk of increased mortality in AF patients. We performed meta-analysis of cohort and 
randomized controlled trials to evaluate pooled effect of digoxin on mortality.
Methods:  MEDLINE, EMBASE, BIOSIS, Cochrane databases, GoogleScholar, conference proceedings and Web of Science from 
inception to October 2014 were searched for studies of patients on digoxin and atrial fibrillation that reported mortality as an outcome 
measure. Two authors independently assessed study quality and extracted data. Random effects model was used to estimate pooled effect 
size as hazard ratio with 95% confidence intervals (CI) and between-study heterogeneity was assessed by I2 method.
results:  Five cohort studies and randomized controlled trials were included. There were a total of 53,335 AF patients that were on digoxin 
and 150,983 that were not on digoxin at baseline. There were a total of 48,912 deaths that occurred in these individuals. In a random 
effects model, digoxin was associated with increased risk of mortality in patients with AF (pooled hazard ratio 1.26; 95% CI 1.16 - 1.37, p 
<0.001). There was very mild heterogeneity observed between the studies (I2 <30%). The individual studies with point estimates and 95% 
CI are shown in the figure.
Conclusion:  Digoxin appears to be associated with increased risk of mortality in patients with AF.
